OMG
VRNA

One Madison Group’s Verona Pharma VRNA Stock Holding History

One Madison Group’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,778
Closed -$2.14M – 31
2025
Q1 		$2.14M Buy
+33,778
New +$2.02M 0.28% 26

Other funds holding VRNA

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

One Madison Group's VRNA Position: Q2 2025 in Review

One Madison Group sold out of Verona Pharma (VRNA) in Q2 2025, closing a stake of 33,778 shares — an estimated $2.14M sold.

One Madison Group first reported a position in VRNA in Q1 2025 and held it in 1 quarter. The position peaked at $2.14M in Q1 2025. 292 funds tracked by Wall St. Rank hold VRNA as of Q2 2025.

  • One Madison Group reported no remaining Verona Pharma position as of Q2 2025 after selling out during the quarter.
  • One Madison Group sold 33,778 Verona Pharma shares in Q2 2025, an estimated $2.14M.
  • One Madison Group first reported a position in Verona Pharma in Q1 2025 and held it in 1 quarter.
  • One Madison Group's Verona Pharma position peaked at $2.14M in Q1 2025.
  • 292 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2025.

Based on One Madison Group's 13F filing for Q2 2025, filed 14 Aug 2025.